•  
  •  
  •  
  •  

2026-03-27 05:09:41

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • EaseMyTrip Enters Exclusive Partnership with MSTC Ltd. to Power Travel Services for Govt Sector
  • Sundaram-Clayton Completes Rs 558.62 Cr Land Sale
  • 3i Infotech Digital BPS Ltd receives order from Mahanagar Gas Ltd
  • AZAD Engineering Ltd signs long term contract with Mitsubishi Heavy Industries Ltd
  • PNGS Gargi Fashion Jewellery Ltd opens new store in Pune

Keywords Selected:  FinalApproval

Stock Report

  • Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
  • Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg
  • Caplin Steriles gets USFDA approval for Desmopressin Acetate Injection
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Efinaconazole Topical Solution, 10%
  • Caplin Steriles gets USFDA approval for Sodium Phosphates Injection
  • Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
  • Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%
  • Caplin Steriles granted final approval by USFDA for Acetaminophen Injection, infusion bags
  • Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
  • Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
  • Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL
  • Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets, 10mg

Latest Post

  • EaseMyTrip Enters Exclusive Partnership with MSTC Ltd. to Power Travel Services for Govt Sector
  • Sundaram-Clayton Completes Rs 558.62 Cr Land Sale
  • 3i Infotech Digital BPS Ltd receives order from Mahanagar Gas Ltd
  • AZAD Engineering Ltd signs long term contract with Mitsubishi Heavy Industries Ltd
  • PNGS Gargi Fashion Jewellery Ltd opens new store in Pune


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025